Pure Global
NCT04574258

Prospective Multicenter Study on Clinical Application of Sonozoid in Thyroid Tumor

Contrast-enhanced Ultrasound in Thyroid Tumor by Sonozoid
Chinese PLA General Hospital·ClinicalTrials.govCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ultrasound
Study type
Observational
Sponsor & location
Primary sponsor
Chinese PLA General Hospital
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2020
End date
Aug 01, 2021
Enrollment
371 participants
Primary outcome

Diagnostic performance of contrast-enhanced ultrasound in thyroid tumor by Sonazoid.

Summary

Sonazoid as a new generation of ultrasound contrast agent. This study based on the features
 of Sonazoid specific angiography and high mechanical index, the role of Sonazoid in the
 differential diagnosis of thyroid benign and malignant tumors was explored.

ICD-10 classifications
Abnormal ultrasonic finding on antenatal screening of motherAntenatal screening for malformations using ultrasound and other physical methodsAntenatal screening for fetal growth retardation using ultrasound and other physical methodsOther diagnostic agentsExamination of ears and hearing
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04574258
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04574258 through Pure Global AI's free database. This phase not specified trial is sponsored by Chinese PLA General Hospital and is currently Completed. The study focuses on Ultrasound. Target enrollment is 371 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.